Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
PFE — Price & Float Short
—— Fair value ★ EPS beat ★ EPS miss —— Target Price
Float Short %

Float Short %

2.46

Margin Of Safety %

39

Put/Call OI Ratio

0.89

EPS Next Q Diff

0.1

EPS Last/This Y

1.59

EPS This/Next Y

-0.13

Price

25.78

Target Price

28.92

Analyst Recom

2.54

Performance Q

-4

Upside

-34.4%

Beta

0.3

Ticker: PFE




22 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-04-21PFE27.310.840.632332432
2026-04-22PFE26.80.840.572382647
2026-04-23PFE26.660.850.972421020
2026-04-24PFE270.870.292486142
2026-04-27PFE26.820.900.312425327
2026-04-28PFE26.470.880.492469325
2026-04-29PFE26.270.870.382535151
2026-04-30PFE26.70.870.462556853
2026-05-01PFE26.330.860.462570010
2026-05-04PFE26.330.880.432459559
2026-05-05PFE26.440.870.752528871
2026-05-06PFE26.50.900.432603107
2026-05-07PFE26.480.900.152623439
2026-05-08PFE25.670.910.942634331
2026-05-11PFE25.820.940.292573873
2026-05-12PFE25.890.930.312623789
2026-05-13PFE25.950.921.442643872
2026-05-14PFE25.750.940.592700525
2026-05-15PFE25.330.940.522718370
2026-05-18PFE25.320.930.662433493
2026-05-19PFE25.680.920.322482205
2026-05-20PFE25.780.890.282538994
DateSymbolLatestP/C OIP/C VolTotal OI
22 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-04-21PFE27.32-21.88591.52.96
2026-04-22PFE26.78-21.88423.72.96
2026-04-23PFE26.66-21.48623.72.96
2026-04-24PFE26.98-21.48862.92.96
2026-04-27PFE26.81-21.48597.92.96
2026-04-28PFE26.48-21.48533.72.96
2026-04-30PFE26.70-21.68934.62.96
2026-05-01PFE26.33-21.68501.42.96
2026-05-04PFE26.31-21.68687.12.96
2026-05-05PFE26.45-21.68778.62.96
2026-05-06PFE26.50-21.68724.72.96
2026-05-07PFE26.49-12.88232.42.96
2026-05-08PFE25.67-12.87825.02.96
2026-05-11PFE25.81-12.38602.82.97
2026-05-13PFE25.96-12.48347.82.97
2026-05-14PFE25.76-12.48190.62.97
2026-05-15PFE25.32-12.48064.42.97
2026-05-18PFE25.33-12.68293.42.96
2026-05-19PFE25.69-12.68497.72.96
2026-05-20PFE25.78-12.88364.52.96
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-04-21PFE0.000.132.33
2026-04-22PFE0.000.132.33
2026-04-23PFE0.000.132.33
2026-04-24PFE0.000.132.33
2026-04-27PFE0.000.422.35
2026-04-28PFE0.000.422.35
2026-04-29PFE0.000.422.35
2026-04-30PFE0.000.422.35
2026-05-01PFE0.000.422.35
2026-05-04PFE0.000.112.35
2026-05-05PFE0.000.112.35
2026-05-06PFE0.000.112.35
2026-05-07PFE0.000.112.35
2026-05-08PFE0.000.110
2026-05-11PFE0.001.492.34
2026-05-12PFE0.001.492.46
2026-05-13PFE0.001.492.46
2026-05-14PFE0.001.492.46
2026-05-15PFE0.001.492.46
2026-05-18PFE0.001.092.46
2026-05-19PFE0.001.092.46
2026-05-20PFE0.001.092.46
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

0.75

Avg. EPS Est. Current Quarter

0.68

Avg. EPS Est. Next Quarter

0.85

Insider Transactions

Institutional Transactions

1.09

Beta

0.3

Average Sales Estimate Current Quarter

14410

Average Sales Estimate Next Quarter

16150

Fair Value

35.83

Quality Score

80

Growth Score

49

Sentiment Score

73

Actual DrawDown %

58.2

Max Drawdown 5-Year %

-59

Target Price

28.92

P/E

19.77

Forward P/E

9.1

PEG

P/S

2.32

P/B

1.63

P/Free Cash Flow

15.5

EPS

1.3

Average EPS Est. Cur. Y​

2.96

EPS Next Y. (Est.)

2.84

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

11.79

Relative Volume

0.92

Return on Equity vs Sector %

-18.7

Return on Equity vs Industry %

-28.9

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

8364.5
PFE Healthcare
$25.78
📉
Swing / Pullback
Buy the dip on strong trends
N/A
0 /100
WEAK
Trend
6/20
Pullback
19/25
Volume
7/15
Valuation
16/20
TP/AR
0/10
Options
4/10
RSI
41.9
Range 1M
29.8%
Sup Dist
1.9%
🚀
Momentum Growth
Ride accelerating trends
N/A
20 /100
WEAK
Momentum
1/25
Growth
3/30
Estimates
4/20
Inst/Vol
5/15
Options
7/10
EPS Yr
-8%
EPS NY
-4.4%
52W%
52.3%
💎
Long-Term Value
Quality companies, undervalued
35 /100
WEAK
🟢 BUY +35.7% upside
Quality
10/30
Valuation
17/30
Growth
2/25
Stability
4/10
LT Trend
2/5
Upside
+35.7%
Quality
80
MoS
39%
Pfizer, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75000
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
PFE

Latest News

Caricamento notizie per PFE
stock quote shares PFE – Pfizer Inc. Stock Price stock today
news today PFE – Pfizer Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch PFE – Pfizer Inc. yahoo finance google finance
stock history PFE – Pfizer Inc. invest stock market
stock prices PFE premarket after hours
ticker PFE fair value insiders trading